Pharmafile Logo

OPEN Health Group Appoints New Leadership

November 18, 2020 |  

OPEN Health Group today announced that Rob Barker has been appointed Chief Executive Officer. Rob succeeds outgoing CEO and Co-Founder, David Rowley, who is stepping down after 10 years. A portfolio company of Amulet Capital Partners, LP, OPEN Health is a leading multi-disciplinary health communications and market access group.

Mr. Barker has approximately 30 years of executive leadership experience in the biopharmaceuticals industry, including multiple roles at leading medical communications and strategy consulting firms. Most recently, he served as CEO of OPEN Health’s Medical Communications practice, having joined the business six years ago.

Mr. Barker expressed his enthusiasm for the continued growth and success of OPEN Health: “I am excited to be leading such a talented and expert team who have been instrumental in growing OPEN Health to its current position. We are now in a place to take even greater strides forward, and I feel confident that our continued focus on client service and scientific excellence will drive increased growth in the business.”

“Rob Barker has proven himself as an outstanding strategic and operational leader, and we are confident that he is the ideal executive to lead OPEN Health through its next exciting stage of growth,” said Ramsey Frank, Managing Partner and co-founder of Amulet. Amulet Partner Nick Amigone added, “Medical Affairs, Medical Communications, Market Access and HEOR have taken on increasingly important roles in bringing new therapies to market. Rob has been instrumental in assembling a suite of best-in-class capabilities at OPEN Health and driving the business to achieve its full potential.”

Mr. Frank added, “David Rowley leaves the business with our enormous thanks. He has grown OPEN Health from an initial idea to a leading global healthcare communications group. All his colleagues at OPEN Health are grateful to him and wish him well for the future. David will work with us in an advisory capacity to ensure a smooth transition.”

Mr. Rowley said “I have been CEO of OPEN Health since its inception, and I am incredibly proud of the company that we have built. This is the right time for me to be stepping down, and I wish Rob and the whole OPEN Health team continued success.”

Pink divider

About OPEN Health

OPEN Health is a multi-disciplinary health communications and market access group, operating across three core business areas: Medical Communications; Patient and Brand Communications; and Value, Informatics and Evidence. OPEN Health was formed in 2011, and whilst working across a broad therapeutic range has a strong focus on oncology, rare diseases and specialist medicines.

For more information on OPEN Health, please visit www.openhealthgroup.com.

About Amulet Capital Partners, LP

Amulet Capital Partners, LP is a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in companies. Amulet Capital Partners focuses on those segments it believes have the most attractive long-term fundamentals with a target investment size generally between $25 million to $150 million.

For additional information, please visit www.amuletcapital.com.

Pink divider

Contacts for OPEN Health:

EU: Carwyn Jones 
carwynjones@openhealthgroup.com
+44 20 3386 4728

USA: Candice Subero
csubero@openhealthgroup.com
+1 240-483-4323

Contact for Amulet Capital Partners:

Melissa Sheer 
melissa@kentplacellc.com
+1 917-690-2199

This content was provided by OPEN Health

Company Details

 Latest Content from  OPEN Health 

OPEN Health expands offering with the launch of a new Learning & Development specialist team

Enhanced expertise to deliver impactful internal training programmes for healthcare clients

Spotlight interview: 15 minutes on healthcare communications in gene therapy

Gavin Jones, Director of Rare Disease, OPEN Health takes 15 minutes to answer some key questions on healthcare communications in gene therapy

OPEN Health becomes sponsor of MedComms Networking

New for 2020, OPEN Health is pleased to announce its sponsorship of MedComms Networking

OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications

Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications

Spotlight interview: 15 minutes on digital in medical communications

Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications

Generating data on long-term outcomes with gene and other advanced therapies

Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’.

Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?

A recent blog, published by Sarah Tressel Gary and Rinah Yamamoto called “Patient-Reported Outcome Data in Oncology Trials - Part 2: Clinical Benefit and Patient Preference”, has sparked our interest....

Spotlight interview: 15 minutes on insights and market research in pharma

Neil Rees, Head of Research, OPEN Health Patient & Brand Communication takes 15 minutes to answer some key questions on insights and market research in pharma

OPEN Health reflections on the World Orphan Drug Congress in Barcelona

Having just returned from a very busy but hugely enjoyable few days at congress, I wanted to share our views on the event and key themes that our healthcare communications...